Literature DB >> 2564681

Increased uptake of methylated low-density lipoprotein induced by noradrenaline in carotid arteries of anaesthetized rabbits.

S Shafi1, N J Cusack, G V Born.   

Abstract

Atherosclerosis is accelerated in hyperlipidaemias but, apart from the concentration of low-density lipoprotein (LDL) in the blood, very little is known about other influences on the disease process. We now provide evidence that in anaesthetized rabbits the atherogenic uptake of LDL by arterial walls is accelerated by noradrenaline at its physiological concentrations in rabbit and human blood. The principle of the experiments was to compare the uptake of intravenously injected, radioactively labelled LDL, methylated to prevent removal by high-affinity receptors, in the two carotid arteries of anaesthetized rabbits after infusing low concentrations of noradrenaline into one carotid and saline as control into the other, the volume rates of infusion being about 1% of the carotid blood flows. Human LDL, which behaves sufficiently like rabbit LDL for these purposes, was prepared, methylated and radio-iodinated by standard methods. At the end of the infusions, the arteries were excised and their radioactivities determined. Noradrenaline infused for 2 h to produce local blood concentrations of nominally 1, 10, 50 and 100 nM significantly increased the LDL radioactivities of the walls of the noradrenaline-infused carotids. Concentrations of nominally 100 nM also increased the LDL radioactivities of the walls of the saline-infused carotids; this was associated with significant increases in their blood noradrenaline concentrations. These results may contribute towards an explanation for the accelerated atherosclerosis and the increased incidence of its clinical manifestations in conditions associated with elevated blood noradrenaline concentrations, including the episodic increases associated with stress and cigarette smoking as well as the more persistent increases caused by phaeochromocytoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2564681     DOI: 10.1098/rspb.1989.0001

Source DB:  PubMed          Journal:  Proc R Soc Lond B Biol Sci        ISSN: 0950-1193


  7 in total

Review 1.  Nuclear medicine and atherosclerosis.

Authors:  H Sinzinger; I Virgolini
Journal:  Eur J Nucl Med       Date:  1990

2.  AP2-NR4A3 transgenic mice display reduced serum epinephrine because of increased catecholamine catabolism in adipose tissue.

Authors:  R Grace Walton; Xiaolin Zhu; Ling Tian; Elizabeth B Heywood; Jian Liu; Helliner S Hill; Jiarong Liu; Dennis Bruemmer; Qinglin Yang; Yuchang Fu; W Timothy Garvey
Journal:  Am J Physiol Endocrinol Metab       Date:  2016-05-10       Impact factor: 4.310

3.  Increase by adrenaline or angiotensin II of the accumulation of low density lipoprotein and fibrinogen by aortic walls in unrestrained conscious rats.

Authors:  L E Cardona-Sanclemente; G V Born
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

4.  Effect of increasing doses of angiotensin II infused into normal and hypertensive Wistar rats on low density lipoprotein and fibrinogen uptake by aortic walls.

Authors:  L E Cardona-Sanclemente; R Medina; G V Born
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

5.  The influence of aspirin on plasma and platelet catecholamine levels, and platelet function in normal man.

Authors:  C C Smith; A P Wilson; D J Betteridge
Journal:  Clin Auton Res       Date:  1993-02       Impact factor: 4.435

6.  Effect of inhibition of nitric oxide synthesis on the uptake of LDL and fibrinogen by arterial walls and other organs of the rat.

Authors:  L E Cardona-Sanclemente; G V Born
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

Review 7.  A review of neuroimaging studies of stressor-evoked blood pressure reactivity: emerging evidence for a brain-body pathway to coronary heart disease risk.

Authors:  Peter J Gianaros; Lei K Sheu
Journal:  Neuroimage       Date:  2009-05-04       Impact factor: 6.556

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.